Item 8.01 Other Events. On August 5, 2026, Apimeds Pharmaceuticals US, Inc. (the “Company”) appointed Dr. Christopher Kim as its Chief Scientific Officer, effective immediately. As Chief Scientific Officer, Dr. Kim will lead the scientific, clinical, and regulatory development of the Company’s APITOX program, including research and development, clinical strategy, regulatory engagement, and activities directed toward obtaining regulatory approvals and advancing the program toward commercialization. Dr. Kim has been closely associated with the APITOX program for many years and possesses extensive scientific, technical, and regulatory expertise relating to its research, development, and clinical advancement. His appointment provides continuity in the program’s leadership and strengthens the Company’s ability to execute its long-term development strategy as it advances APITOX through the regulatory process and toward commercialization.

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description ──────────────────────────────────────────────────────────────────────────────────────────────── 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURE